Axela Inc.
Director, Finance & Corporate Development
(416) 260-9050 x2243
o.gordon@axelabiosensors.com.
Axela is commercializing products that accelerate the validation of protein biomarkers from discovery into routine clinical practice. The Company has developed a proprietary breakthrough technology, Diffractive Optics Technology (dot(tm)), which enables the real-time detection and quantitation of protein binding events in complex media. Axela has developed this technology into the dotLab(tm) System, a commercially available bench-top laboratory system that delivers simple, affordable, yet highly sensitive protein based assays.
To leverage the opportunities that dot(tm) creates, Axela has assembled a management team with extensive experience in diagnostic and research product development and commercialization. Axela is a privately-held company based in Toronto, Canada whose major investor is VenGrowth Asset Management Inc., one of Canada's premier private equity managers. For more information, please visit www.axelabiosensors.com.
BROWSE TENANTS
- AIM Therapeutics Inc.
- Ambit Biosciences
- ApoPharma Inc.
- ArcticDx Inc.
- AstraZeneca Canada Inc.
- Axela Inc.
- AXS Biomedical Animation Studio
- BioDiscovery Toronto
- BioFinance Canada
- BioQuest Innovations Inc.
- Biosign Technologies Inc.
- The Biotechnology Initiative
- BML Canada Limited
- Canadian Biotechnology Education Resource Centre (CBERC)
- Cascade Therapeutics Inc.
- Cassandra Capital L.P.
- Celtic House Venture Partners
- Clera Inc.
- Constab International Inc.
- Critical Outcome Technologies Inc.
- CVCA - Canada’s Venture Capital & Private Equity Association
- Diagnostic Systems Laboratories
- GlaxoSmithKline Inc.
- htx.ca - The Health Technology Exchange
- The Innovations Group, University of Toronto
- iLOOKABOUT Inc.
- Innovation Institute of Ontario
- Interface Biologics
- InVisage Technologies
- In Vitro Drug Safety & BioTechnology
- Kanata Chemical Technologies
- Larial Proteomics
- MaRS Landing
- The Martin Prosperity Institute
- McLaughlin Centre for Molecular Medicine
- McLaughlin-Rotman Centre for Global Health - Program on Life Sciences, Ethics and Policy
- Merck Frosst Canada Ltd.
- NeurAxon Inc.
- Ontario Cancer Biomarker Network (OCBN)
- Octopz Inc.
- Ogilvy Renault LLP
- Ontario Institute for Cancer Research
- Ontario Geonomics Institute
- Ontario Innovation Trust
- Ontario Society for Excellence in Techology Transfer
- Ozmosis Research
- RBC Royal Bank
- RBC Venture Partners
- Receptor Therapeutics Inc.
- Sigma Analysis & Management Ltd.
- Skymeter Corporation
- Toronto Region Research Alliance
- Transition Therapeutics
- University Hospital Network Technology Development & Commercialization Office
- University Health Network
- University of Toronto Asset Management Corporation
- University of Waterloo
- YYZ/Blue Sky Capital Corporation